NOVARTIS Ebit from 2010 to 2026
| NOT Stock | 142.05 1.65 1.18% |
EBIT | First Reported 2010-12-31 | Previous Quarter 19.8 B | Current Value 14.6 B | Quarterly Volatility 4 B |
Check NOVARTIS N financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NOVARTIS N's main balance sheet or income statement drivers, such as Discontinued Operations of 13 B, Interest Expense of 666.2 M or Selling General Administrative of 11.1 B, as well as many indicators such as . NOVARTIS financial statements analysis is a perfect complement when working with NOVARTIS N Valuation or Volatility modules.
NOVARTIS | Ebit |
The evolution of Ebit for NOVARTIS N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NOVARTIS N compares to historical norms and industry peers.
Latest NOVARTIS N's Ebit Growth Pattern
Below is the plot of the Ebit of NOVARTIS N over the last few years. It is NOVARTIS N's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NOVARTIS N's overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
NOVARTIS Ebit Regression Statistics
| Arithmetic Mean | 14,151,579,412 | |
| Geometric Mean | 13,606,850,729 | |
| Coefficient Of Variation | 28.55 | |
| Mean Deviation | 3,581,839,446 | |
| Median | 14,610,200,000 | |
| Standard Deviation | 4,039,937,443 | |
| Sample Variance | 16321094.5T | |
| Range | 12.7B | |
| R-Value | 0.70 | |
| Mean Square Error | 8894237.7T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 559,507,721 | |
| Total Sum of Squares | 261137512.7T |
NOVARTIS Ebit History
About NOVARTIS N Financial Statements
NOVARTIS N shareholders use historical fundamental indicators, such as Ebit, to determine how well the company is positioned to perform in the future. Although NOVARTIS N investors may analyze each financial statement separately, they are all interrelated. The changes in NOVARTIS N's assets and liabilities, for example, are also reflected in the revenues and expenses on on NOVARTIS N's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| EBIT | 19.8 B | 14.6 B | |
| EBITDA | 18.8 B | 22 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NOVARTIS Stock Analysis
When running NOVARTIS N's price analysis, check to measure NOVARTIS N's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NOVARTIS N is operating at the current time. Most of NOVARTIS N's value examination focuses on studying past and present price action to predict the probability of NOVARTIS N's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NOVARTIS N's price. Additionally, you may evaluate how the addition of NOVARTIS N to your portfolios can decrease your overall portfolio volatility.